ALRN Stock Overview
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Aileron Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.25 |
| 52 Week High | US$7.12 |
| 52 Week Low | US$1.01 |
| Beta | 2.24 |
| 1 Month Change | -21.44% |
| 3 Month Change | 0.47% |
| 1 Year Change | 169.02% |
| 3 Year Change | -81.84% |
| 5 Year Change | -87.79% |
| Change since IPO | -98.03% |
Recent News & Updates
Recent updates
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky
Aug 18
Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?
Dec 30Aileron Therapeutics: An Assessment On A Lottery Ticket
Oct 21Aileron Therapeutics: Solving Chemotherapy's Toxicity
May 01Aileron Therapeutics +31% on insider buying more shares
Jan 08Aileron raises $40M via equity offering
Jan 06Aileron Therapeutics EPS in-line
Nov 13Shareholder Returns
| ALRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -26.9% | -5.0% | -3.5% |
| 1Y | 169.0% | -1.7% | 20.2% |
Return vs Industry: ALRN exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: ALRN exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| ALRN volatility | |
|---|---|
| ALRN Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALRN's share price has been volatile over the past 3 months.
Volatility Over Time: ALRN's weekly volatility has decreased from 22% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 6 | James Windsor | www.aileronrx.com |
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.
Aileron Therapeutics, Inc. Fundamentals Summary
| ALRN fundamental statistics | |
|---|---|
| Market cap | US$90.80m |
| Earnings (TTM) | -US$15.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.6x
P/E RatioIs ALRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$15.73m |
| Earnings | -US$15.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALRN perform over the long term?
See historical performance and comparison